secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001104659-24-001139
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharmaceuticals licenses LB54640 from LG Chem for $60M upfront plus $40M deferred
--------------------------------------------------------------------------------

- License deal: $40M cash + $20M stock upfront; additional $40M cash due 18 months after effective date.
- Up to $205M in regulatory and sales milestones; low-to-mid single-digit royalties on MC4R portfolio starting 2029.
- Rhythm assumes sponsorship of two Phase 2 studies: SIGNAL (hypothalamic obesity, ~28 patients) and ROUTE (POMC/LEPR deficiency, 5 patients).
- Cash guidance updated: existing cash sufficient into H2 2025, including $80M fixed payments to LG Chem.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465924001139/0001104659-24-001139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465924001139/tm2332524d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-001139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer